Ceramides are signals of fatty acid excess that accumulate when a cell's energetic needs have been met and its nutrient storage has reached capacity. As these sphingolipids accrue, they alter the metabolism and survival of cells throughout the body including in the heart, liver, blood vessels, skeletal muscle, brain, and kidney. These ceramide actions elicit the tissue dysfunction that underlies cardiometabolic diseases such as diabetes, coronary artery disease, metabolic-associated steatohepatitis, and heart failure. Here, we review the biosynthesis and degradation pathways which maintain ceramide levels in normal physiology and discuss how the loss of ceramide homeostasis drives cardiometabolic pathologies. We highlight signaling nodes that sense small changes in ceramides, and in turn reprogram cellular metabolism and stimulate apoptosis. Lastly, we evaluate the emerging therapeutic utility of these unique lipids as biomarkers that forecast disease risk and as targets of ceramide-lowering interventions that ameliorate disease.
Keyphrases
- heart failure
- skeletal muscle
- coronary artery disease
- fatty acid
- cell cycle arrest
- oxidative stress
- induced apoptosis
- type diabetes
- cardiovascular disease
- cell death
- atrial fibrillation
- percutaneous coronary intervention
- single cell
- insulin resistance
- endoplasmic reticulum stress
- stem cells
- metabolic syndrome
- radiation therapy
- physical activity
- cell therapy
- squamous cell carcinoma
- lymph node
- cardiovascular events
- resting state
- adipose tissue
- functional connectivity
- aortic valve
- tyrosine kinase
- aortic stenosis
- ejection fraction
- sentinel lymph node
- rectal cancer
- free survival
- liver fibrosis
- glycemic control